Hyperbaric Oxygen Therapy for PTSD: Threshold Effect for Sustained Symptom Improvement in a Biologically Based Treatment

高压氧疗法治疗创伤后应激障碍:基于生物学的治疗中持续症状改善的阈值效应

阅读:2

Abstract

OBJECTIVE: Emerging evidence suggests that hyperbaric oxygen therapy (HBOT) promotes neuroplasticity and alleviates symptoms in individuals with post-traumatic stress disorder (PTSD). As a biologically based treatment, HBOT may demonstrate a threshold effect, wherein sufficient treatment leads to sustained symptom improvement, while insufficient treatment results in diminishing benefits. This study tested the threshold hypothesis reanalyzing the end of treatment and a 3-month follow-up symptoms scores of a randomized controlled trial (RCT) comparing HBOT to sham treatment in 56 male veterans with treatment-resistant PTSD. METHODS: A post hoc analysis was conducted on data from the RCT. The elbow method identifies thresholds in the relationship between end-of-treatment improvement and follow-up outcomes. Spearman's rank correlation was used to assess the relationship between changes in cluster-specific symptoms and total CAPS scores at the end of treatment and at follow-up evaluation. RESULTS: Participants achieving ≥ 35% improvement by the end of treatment demonstrated continued improvement at follow-up (p = 2e(-6)). Significant correlations were observed between changes in each of the symptom clusters and total CAPS scores, with the strongest correlation in intrusive symptoms (Cluster B, r = 0.74, p = 10e(-4) and r = 0.80, p = 10e(-4)). Changes in avoidance (Cluster C, r = 0.70, p = 10e(-4)) at the end of treatment were the best predictors of follow-up improvements. CONCLUSIONS: A threshold effect is evident in HBOT treatment for PTSD, where ≥ 35% improvement posttreatment predicts continued gains. Symptom reduction beyond the threshold may serve as a target for HBOT when prescribed for PTSD. The suggested underlying physiological mechanisms, involving bistable circuit dynamics, justify evaluating potential threshold effect in other treatment modalities. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT04518007.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。